Celtaxsys Presents Clinical Data on Oral CTX-4430 at 2015 European Cystic Fibrosis Conference: Positive Impacts on Key Biomarkers in Patients with CF
June 10, 2015
Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from inflammatory diseases, including those with rare and orphan inflammatory diseases, announced today data from Phase 1 clinical trials of CTX-4430 will be presented at the 2015 Meeting of the European Cystic Fibrosis Society in Brussels on Friday, Jun 12, 2015.
Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne
June 8, 2015
Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII.
Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial
June 2, 2015
Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from inflammatory diseases, including those with rare and orphan inflammatory diseases, announced today that it has received a development award for $5 million from Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT"), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation
Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris – Recruitment of Patients to Commence Immediately
April 7, 2015
Atlanta-based pharmaceutical company Celtaxsys, Inc. announced today that it has received regulatory clearance to commence the phase 2 trial for its flagship compound, CTX-4430, in patients with moderate to severe facial acne vulgaris.
Celtaxsys Lead Candidate Granted Orphan Designation in Cystic Fibrosis by FDA
February 3, 2015
Celtaxsys, Inc., a clinical stage biotechnology company focused on advancing break through medicines to treat inflammatory mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its once daily, oral leukotriene A4 hydrolase inhibitor (CTX-4430) for the treatment of cystic fibrosis (CF).
Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer
November 6, 2014
Celtaxsys, Inc. is pleased to announce the appointment of Sanjeev Ahuja, MD, MBA, FACP as Chief Medical Officer, effective November 1, 2014.
Prof. Stuart Elborn presentation at ECFS
June 13, 2014
During the Late Breaking Science Session of the ECFS Meeting in Gothenburg, Sweden, Prof. Elborn presented, "Clinical pharmacodynamics of CTX-4430, a potential new oral anti-inflammatory treatment for CysticFibrosis".
Celtaxsys is granted EU orphan designation in Cystic Fibrosis for lead asset CTX-4430
Celtaxsys, a US biopharmaceutical company, focused on the development of CTX-4430, a novel leukotriene A4 hydrolase inhibitor, announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has issued a positive opinion on an application for orphan medicinal product status for Celtasys' CTX-4430 for the treatment of Cystic Fibrosis.
Celtaxsys presenting at 2014 North American Cystic Fibrosis Foundation annual meeting
October 9, 2014
Celtaxsys, Inc. a privately held biotechnology company announced today that new data on their lead compound, once daily, oral CTX-4430 will be presented at the 2014 North American Cystic Fibrosis Foundation annual meeting, October 9-12
Celtaxsys to attend the European Cystic Fibrosis Society Meeting
Members of Celtaxsys will be attending the ECFS meeting from June 11-14 in Gothenburg, Sweden. For more information please visit https://www.ecfs.eu/home
Celtaxsys Announces new President and Chief Executive Officer Greg Duncan
January 8, 2014
Atlanta, GA - The Celtaxsys Board of Directors today announced that Greg Duncan has been appointed as President and Chief Executive Officer (CEO) and will join the board of directors effective immediately. Mr. Duncan joins Celtaxsys following his most recent role as an Executive Committee member and President of North America for Brussels based UCB, prior to which he served as a Senior Vice-President at Pfizer where his duties included leading US marketing, as well as President of their Latin America operations. Greg will be based in Atlanta, Georgia.
Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
September 16, 2013
ATLANTA, GA – Atlanta-based pharmaceutical discovery and development company, Celtaxsys, has successfully completed the first of two clinical trials in its Phase 1 program, and the first trial conducted through its Australia subsidiary, Celtaxsys Aus Pty Ltd.In this First-in-Human trial, CTX-4430 was administered orally to Healthy Volunteers in escalating doses (up to 200 mg/day for 2 weeks) and was well-tolerated at all doses. Results of the trial will be presented at the 27th Annual North American Cystic Fibrosis Conference in October.
Celtaxsys Restructures, Enhances Operational Focus.
September 9, 2013
ATLANTA, GA – Celtaxsys, Inc., an Atlanta-based pharmaceutical discovery and development company, announced today that it has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease.
Celtaxsys Brings Leading Researchers in Respiratory Diseases Together to Serve on Medical Advisory Panel
January 23, 2013
SAN FRANCISCO, CA – Celtaxsys, Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced the appointments of Edward E. Philpot, M.D, J. Stuart Elborn, M.D., Richard B. Moss, M.D., Steven M. Rowe, M.D., M.S.P.H., and Michael S. Schechter, M.D., M.P.H., to its new Medical Advisory Panel.
Celtaxsys Initiates Phase 1 Study of CTX-4430 Oral Treatment for Pulmonary Inflammation
January 3, 2013
SAN FRANCISCO, CA – Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).
Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation
January 5, 2013
San Francisco, Calif. /PRNewswire / -- Celtaxsys, Inc. a privately held biotechnology company announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
Copyright © 2014 Celtaxsys. All rights reserved.